Latest Anacor Pharmaceuticals (ANAC) Headlines
Post# of 102
Posted On: 03/13/2014 5:12:16 AM
Latest Anacor Pharmaceuticals (ANAC) Headlines
Anacor Pharmaceuticals elects Vince Ippolito as EVP
M2 - Tue Mar 11, 3:16AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (ANAC) reported on Monday the addition of Vince Ippolito as its executive vice president and chief commercial officer.
Anacor Pharmaceuticals Announces Appointment of Vince Ippolito as Chief Commercial Officer
Business Wire - Mon Mar 10, 7:30AM CDT
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today the appointment of Vince Ippolito as Executive Vice President and Chief Commercial Officer. Mr. Ippolito has over 25 years of experience leading specialty medical sales and marketing efforts at Valeant Pharmaceuticals, Inc. (Valeant), Medicis Pharmaceutical Corporation (Medicis) and Novartis AG.
Anacor Pharmaceuticals Announces 2013 Fourth Quarter and Year End Financial Results Conference Call and Webcast
Business Wire - Thu Mar 06, 3:30PM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the fourth quarter and year ended December 31, 2013 on Thursday, March 13, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company's financial results and recent developments. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com and will be available for three months following the call.
Update on Anacor's AN2728 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:50PM CST
Anacor successfully completed an end-of-phase II meeting with the FDA regarding its atopic dermatitis candidate, AN2728
Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the Treatment of Mild-to-Moderate Atopic Dermatitis With AN2728
Business Wire - Thu Feb 27, 6:36AM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) for the topical treatment of mild-to-moderate atopic dermatitis with AN2728 Ointment, 2%, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects 10% - 20% of infants and young children.
Anacor Pharmaceuticals to Present at the Cowen & Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 3:00PM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Geoff Parker, the company's Chief Financial Officer, will provide a company overview at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 3:30 p.m. ET in Boston, Massachusetts. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following the presentation.
NuScale Power Successfully Completes Helical Coil Steam Generator Testing Activities
Business Wire - Tue Feb 25, 7:02AM CST
NuScale Power, LLC announced today that it recently successfully completed its helical coil steam generator (HCSG) testing activities at the SIET S.p.A. (SIET) facilities in Piacenza, Italy, and that during that same time period, the U.S. Nuclear Regulatory Commission (NRC) conducted a successful quality assurance (QA) inspection of the testing activities. The result of the inspection was a rare outcome in that the NRC concluded with no findings, observations, violations, recommendations or non-conformances identified.
Contact Dermatitis - Pipeline Review, H2 2013 Report
M2 - Mon Feb 17, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxk6vr/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2013" report to their offering. 'Contact Dermatitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Contact Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contact Dermatitis. Scope - A snapshot of the global therapeutic scenario for Contact Dermatitis. - A review of the Contact Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Contact Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Contact Dermatitis Overview Therapeutics Development Pipeline Products for Contact Dermatitis - Overview Pipeline Products for Contact Dermatitis - Comparative Analysis Contact Dermatitis - Therapeutics under Development by Companies Contact Dermatitis - Pipeline Products Glance Clinical Stage Products Early Stage Products Contact Dermatitis - Products under Development by Companies Contact Dermatitis - Companies Involved in Therapeutics Development Contact Dermatitis - Therapeutics Assessment Drug Profiles MRX-6 - Drug Profile RTU-1096 - Drug Profile MAM-06.301 - Drug Profile AN-3485 - Drug Profile HPT-721 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned R-Tech Ueno, Ltd. Marinomed Biotechnologie GmbH Anacor Pharmaceuticals, Inc. Celsus Therapeutics Plc Hapten Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/hxk6vr/contact About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Anacor Pharmaceuticals Announces Publication of Article Describing Boron-Containing Compounds and Their Relevance to Dermatology
Business Wire - Thu Feb 13, 7:30AM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that a peer-reviewed article describing the recent progress of boron-based compounds in medicine and the properties of these compounds that support their development for the treatment of various skin disorders will be published in the February 17, 2014 edition of the Journal of Clinical and Aesthetic Dermatology. "From the Test Tube to the Treatment Room: Fundamentals of Boron-Containing Compounds and Their Relevance to Dermatology" is co-authored by James Q. Del Rosso, D.O., F.A.O.C.D., dermatologist in private practice at Las Vegas Skin and Cancer Clinics in Henderson, Nevada and Clinical Professor of Dermatology at Touro University College of Osteopathic Medicine in Henderson, Nevada and Jacob. J. Plattner, Ph.D., Senior Vice President of Research, Anacor Pharmaceuticals.
Skin Infections - Pipeline Review, H2 2013 Research Report
M2 - Fri Jan 31, 2:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/dq4mw3/skin_infections) has announced the addition of the "Skin Infections - Pipeline Review, H2 2013" report to their offering. 'Skin Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Infections. Skin Infections - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources Scope - A snapshot of the global therapeutic scenario for Skin Infections. - A review of the Skin Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Skin Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Takeda Pharmaceutical Company Limited Amorepacific Corporation Toyama Chemical Co., Ltd. Foamix Ltd. Anacor Pharmaceuticals, Inc. Lytix Biopharma AS MGB Biopharma Limited Pergamum AB Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/dq...infections About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Anacor Pharmaceuticals (ANAC) Jumps: Stock Rises 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 8:21AM CST
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares rise by over 9% on the day.
Anacor Pharmaceuticals Inc: The Best Performing Biotechs of 2013
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 26, 11:08AM CST
With the Nasdaq Biotechnology Index up 65% since the start of the year, it's clear that the biotech sector performed extraordinarily well in 2013-but which stocks were the biggest winners? Several small-cap and mid-cap biotech companies posted...
Anacor Pharmaceuticals Is Not for Everyone
at The Street - Thu Dec 19, 5:00AM CST
This stock isn't for widows and orphans. It's for an aggressive portfolio.
Senior Appointments, Stock Splits, New Guidelines, Positive Results, and Clinical Trial Updates - Research Report on Receptos, MEDNAX, CombiMatrix, Anacor, and Idera
PR Newswire - Tue Dec 10, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Chronic Inflammation - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/wstllt/chronic) has announced the addition of the "Chronic Inflammation - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Chronic Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Inflammation. Chronic Inflammation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Chronic Inflammation. - A review of the Chronic Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Inflammation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Chronic Inflammation. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Chronic Inflammation pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Anacor Pharmaceuticals - Biocure pharm - Biolink Group - Dompe Farmaceutici - Dynamis Therapeutics - Italfarmaco - KAEL-GemVax - Phenex Pharmaceuticals - Reata Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wstllt/chronic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Nasdaq stocks posting largest percentage increases
AP - Fri Dec 06, 12:33PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
5 Stocks Poised for Breakouts
at The Street - Mon Dec 02, 10:00AM CST
These stocks look ready to break out and trade higher from current levels.
Research Report: Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2013
M2 - Mon Dec 02, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/frfc4l/athletes_foot) has announced the addition of the "Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2013" report to their offering. 'Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Athlete's Foot (Tinea Pedis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Athlete's Foot (Tinea Pedis). Scope - A snapshot of the global therapeutic scenario for Athlete's Foot (Tinea Pedis). - A review of the Athlete's Foot (Tinea Pedis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Athlete's Foot (Tinea Pedis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Valeant Pharmaceuticals International Watson Pharmaceuticals, Inc. Quinnova Pharmaceuticals, Inc. Helix BioMedix, Inc. Anacor Pharmaceuticals, Inc. Viamet Pharmaceuticals, Inc. FTA Therapeutics, LLC Laboratorio Teuto Brasileiro For more information visit http://www.researchandmarkets.com/research/fr...letes_foot About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Anacor Pharmaceuticals elects Vince Ippolito as EVP
M2 - Tue Mar 11, 3:16AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (ANAC) reported on Monday the addition of Vince Ippolito as its executive vice president and chief commercial officer.
Anacor Pharmaceuticals Announces Appointment of Vince Ippolito as Chief Commercial Officer
Business Wire - Mon Mar 10, 7:30AM CDT
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today the appointment of Vince Ippolito as Executive Vice President and Chief Commercial Officer. Mr. Ippolito has over 25 years of experience leading specialty medical sales and marketing efforts at Valeant Pharmaceuticals, Inc. (Valeant), Medicis Pharmaceutical Corporation (Medicis) and Novartis AG.
Anacor Pharmaceuticals Announces 2013 Fourth Quarter and Year End Financial Results Conference Call and Webcast
Business Wire - Thu Mar 06, 3:30PM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the fourth quarter and year ended December 31, 2013 on Thursday, March 13, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company's financial results and recent developments. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com and will be available for three months following the call.
Update on Anacor's AN2728 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:50PM CST
Anacor successfully completed an end-of-phase II meeting with the FDA regarding its atopic dermatitis candidate, AN2728
Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the Treatment of Mild-to-Moderate Atopic Dermatitis With AN2728
Business Wire - Thu Feb 27, 6:36AM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) for the topical treatment of mild-to-moderate atopic dermatitis with AN2728 Ointment, 2%, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects 10% - 20% of infants and young children.
Anacor Pharmaceuticals to Present at the Cowen & Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 3:00PM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Geoff Parker, the company's Chief Financial Officer, will provide a company overview at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 3:30 p.m. ET in Boston, Massachusetts. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following the presentation.
NuScale Power Successfully Completes Helical Coil Steam Generator Testing Activities
Business Wire - Tue Feb 25, 7:02AM CST
NuScale Power, LLC announced today that it recently successfully completed its helical coil steam generator (HCSG) testing activities at the SIET S.p.A. (SIET) facilities in Piacenza, Italy, and that during that same time period, the U.S. Nuclear Regulatory Commission (NRC) conducted a successful quality assurance (QA) inspection of the testing activities. The result of the inspection was a rare outcome in that the NRC concluded with no findings, observations, violations, recommendations or non-conformances identified.
Contact Dermatitis - Pipeline Review, H2 2013 Report
M2 - Mon Feb 17, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxk6vr/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2013" report to their offering. 'Contact Dermatitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Contact Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contact Dermatitis. Scope - A snapshot of the global therapeutic scenario for Contact Dermatitis. - A review of the Contact Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Contact Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Contact Dermatitis Overview Therapeutics Development Pipeline Products for Contact Dermatitis - Overview Pipeline Products for Contact Dermatitis - Comparative Analysis Contact Dermatitis - Therapeutics under Development by Companies Contact Dermatitis - Pipeline Products Glance Clinical Stage Products Early Stage Products Contact Dermatitis - Products under Development by Companies Contact Dermatitis - Companies Involved in Therapeutics Development Contact Dermatitis - Therapeutics Assessment Drug Profiles MRX-6 - Drug Profile RTU-1096 - Drug Profile MAM-06.301 - Drug Profile AN-3485 - Drug Profile HPT-721 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned R-Tech Ueno, Ltd. Marinomed Biotechnologie GmbH Anacor Pharmaceuticals, Inc. Celsus Therapeutics Plc Hapten Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/hxk6vr/contact About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Anacor Pharmaceuticals Announces Publication of Article Describing Boron-Containing Compounds and Their Relevance to Dermatology
Business Wire - Thu Feb 13, 7:30AM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that a peer-reviewed article describing the recent progress of boron-based compounds in medicine and the properties of these compounds that support their development for the treatment of various skin disorders will be published in the February 17, 2014 edition of the Journal of Clinical and Aesthetic Dermatology. "From the Test Tube to the Treatment Room: Fundamentals of Boron-Containing Compounds and Their Relevance to Dermatology" is co-authored by James Q. Del Rosso, D.O., F.A.O.C.D., dermatologist in private practice at Las Vegas Skin and Cancer Clinics in Henderson, Nevada and Clinical Professor of Dermatology at Touro University College of Osteopathic Medicine in Henderson, Nevada and Jacob. J. Plattner, Ph.D., Senior Vice President of Research, Anacor Pharmaceuticals.
Skin Infections - Pipeline Review, H2 2013 Research Report
M2 - Fri Jan 31, 2:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/dq4mw3/skin_infections) has announced the addition of the "Skin Infections - Pipeline Review, H2 2013" report to their offering. 'Skin Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Infections. Skin Infections - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources Scope - A snapshot of the global therapeutic scenario for Skin Infections. - A review of the Skin Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Skin Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Takeda Pharmaceutical Company Limited Amorepacific Corporation Toyama Chemical Co., Ltd. Foamix Ltd. Anacor Pharmaceuticals, Inc. Lytix Biopharma AS MGB Biopharma Limited Pergamum AB Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/dq...infections About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Anacor Pharmaceuticals (ANAC) Jumps: Stock Rises 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 8:21AM CST
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares rise by over 9% on the day.
Anacor Pharmaceuticals Inc: The Best Performing Biotechs of 2013
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 26, 11:08AM CST
With the Nasdaq Biotechnology Index up 65% since the start of the year, it's clear that the biotech sector performed extraordinarily well in 2013-but which stocks were the biggest winners? Several small-cap and mid-cap biotech companies posted...
Anacor Pharmaceuticals Is Not for Everyone
at The Street - Thu Dec 19, 5:00AM CST
This stock isn't for widows and orphans. It's for an aggressive portfolio.
Senior Appointments, Stock Splits, New Guidelines, Positive Results, and Clinical Trial Updates - Research Report on Receptos, MEDNAX, CombiMatrix, Anacor, and Idera
PR Newswire - Tue Dec 10, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Chronic Inflammation - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/wstllt/chronic) has announced the addition of the "Chronic Inflammation - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Chronic Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Inflammation. Chronic Inflammation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Chronic Inflammation. - A review of the Chronic Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Inflammation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Chronic Inflammation. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Chronic Inflammation pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Anacor Pharmaceuticals - Biocure pharm - Biolink Group - Dompe Farmaceutici - Dynamis Therapeutics - Italfarmaco - KAEL-GemVax - Phenex Pharmaceuticals - Reata Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wstllt/chronic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Nasdaq stocks posting largest percentage increases
AP - Fri Dec 06, 12:33PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
5 Stocks Poised for Breakouts
at The Street - Mon Dec 02, 10:00AM CST
These stocks look ready to break out and trade higher from current levels.
Research Report: Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2013
M2 - Mon Dec 02, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/frfc4l/athletes_foot) has announced the addition of the "Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2013" report to their offering. 'Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Athlete's Foot (Tinea Pedis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Athlete's Foot (Tinea Pedis). Scope - A snapshot of the global therapeutic scenario for Athlete's Foot (Tinea Pedis). - A review of the Athlete's Foot (Tinea Pedis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Athlete's Foot (Tinea Pedis) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Valeant Pharmaceuticals International Watson Pharmaceuticals, Inc. Quinnova Pharmaceuticals, Inc. Helix BioMedix, Inc. Anacor Pharmaceuticals, Inc. Viamet Pharmaceuticals, Inc. FTA Therapeutics, LLC Laboratorio Teuto Brasileiro For more information visit http://www.researchandmarkets.com/research/fr...letes_foot About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
(0)
(0)Anacor Pharmaceuticals (ANAC) Stock Research Links
Scroll down for more posts ▼